Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,026
archived clinical trials in
Epilepsy

Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated:  12/14/2017
VCU Medical Center
mi
from
Richmond, VA
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated: 12/14/2017
VCU Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
Emory Healthcare
mi
from
Atlanta, GA
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
Emory Healthcare
mi
from
Atlanta, GA
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
University of Illinois College of Medicine at Peoria
mi
from
Peoria, IL
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
University of Illinois College of Medicine at Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
University of Louisville Hospital
mi
from
Louisville, KY
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
University of Louisville Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
Cornell University
mi
from
New York, NY
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
Covenant Hospital
mi
from
Lubbock, TX
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
Covenant Hospital
mi
from
Lubbock, TX
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
St. Luke's Milwaukee
mi
from
Milwaukee, WI
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
St. Luke's Milwaukee
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
UZ Gasthuisberg
mi
from
Leuven,
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
UZ Gasthuisberg
mi
from
Leuven,
Click here to add this to my saved trials
A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug
An Open-label Eslicarbazepine Acetate Long-term Safety and Tolerability Study in Children and Adolescents (4 - 17 Years)
Status: Enrolling
Updated:  1/11/2018
Child Neurology Specialists / Clinical Research Center of Nevada, LLC
mi
from
Henderson, NV
A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug
An Open-label Eslicarbazepine Acetate Long-term Safety and Tolerability Study in Children and Adolescents (4 - 17 Years)
Status: Enrolling
Updated: 1/11/2018
Child Neurology Specialists / Clinical Research Center of Nevada, LLC
mi
from
Henderson, NV
Click here to add this to my saved trials
Multimodal Functional Neuroimaging in Epilepsy Patients
Multimodal Functional Neuroimaging in Epilepsy Patients
Status: Enrolling
Updated:  1/18/2018
Biomedical Engineering Department
mi
from
Minneapolis, MN
Multimodal Functional Neuroimaging in Epilepsy Patients
Multimodal Functional Neuroimaging in Epilepsy Patients
Status: Enrolling
Updated: 1/18/2018
Biomedical Engineering Department
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
Status: Enrolling
Updated:  1/19/2018
Bio-Kinetics Clinical Applications, Inc .
mi
from
Springfield, MO
Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
Status: Enrolling
Updated: 1/19/2018
Bio-Kinetics Clinical Applications, Inc .
mi
from
Springfield, MO
Click here to add this to my saved trials
High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy
High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy
Status: Enrolling
Updated:  1/24/2018
Boston Children's Hospital - Neurology
mi
from
Boston, MA
High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy
High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy
Status: Enrolling
Updated: 1/24/2018
Boston Children's Hospital - Neurology
mi
from
Boston, MA
Click here to add this to my saved trials
High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy
High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy
Status: Enrolling
Updated:  1/24/2018
Neurology
mi
from
New York, NY
High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy
High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy
Status: Enrolling
Updated: 1/24/2018
Neurology
mi
from
New York, NY
Click here to add this to my saved trials
Ketogenic Diet Program for Epilepsy
Ketogenic Diet Program for Epilepsy
Status: Enrolling
Updated:  1/26/2018
Shriners Hospitals for Children - Honolulu
mi
from
Honolulu, HI
Ketogenic Diet Program for Epilepsy
Ketogenic Diet Program for Epilepsy
Status: Enrolling
Updated: 1/26/2018
Shriners Hospitals for Children - Honolulu
mi
from
Honolulu, HI
Click here to add this to my saved trials
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status: Enrolling
Updated:  2/5/2018
Consultans in Epilepsy & Neurology, PLLC
mi
from
Boise, ID
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status: Enrolling
Updated: 2/5/2018
Consultans in Epilepsy & Neurology, PLLC
mi
from
Boise, ID
Click here to add this to my saved trials
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status: Enrolling
Updated:  2/5/2018
Bluegrass Epilepsy Research
mi
from
Lexington, KY
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status: Enrolling
Updated: 2/5/2018
Bluegrass Epilepsy Research
mi
from
Lexington, KY
Click here to add this to my saved trials
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status: Enrolling
Updated:  2/5/2018
Mid-Atlantic Epilepsy Center
mi
from
Bethesda, MD
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status: Enrolling
Updated: 2/5/2018
Mid-Atlantic Epilepsy Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status: Enrolling
Updated:  2/5/2018
Minneapolis Clinic of Neurology
mi
from
Golden Valley, MN
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status: Enrolling
Updated: 2/5/2018
Minneapolis Clinic of Neurology
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status: Enrolling
Updated:  2/5/2018
Clinilabs Inc.
mi
from
New York, NY
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status: Enrolling
Updated: 2/5/2018
Clinilabs Inc.
mi
from
New York, NY
Click here to add this to my saved trials
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status: Enrolling
Updated:  2/5/2018
NeurologicalClinic of Texas, P.A.
mi
from
Dallas, TX
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status: Enrolling
Updated: 2/5/2018
NeurologicalClinic of Texas, P.A.
mi
from
Dallas, TX
Click here to add this to my saved trials
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status: Enrolling
Updated:  2/5/2018
The More foundation/The Core Institute
mi
from
Sun City, AZ
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status: Enrolling
Updated: 2/5/2018
The More foundation/The Core Institute
mi
from
Sun City, AZ
Click here to add this to my saved trials
Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy
Evaluation of the Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy: a Pilot Study.
Status: Enrolling
Updated:  2/22/2018
MidAtlantic Epilepsy and Sleep Center
mi
from
Bethesda, MD
Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy
Evaluation of the Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy: a Pilot Study.
Status: Enrolling
Updated: 2/22/2018
MidAtlantic Epilepsy and Sleep Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI
Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI
Status: Enrolling
Updated:  3/12/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI
Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI
Status: Enrolling
Updated: 3/12/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Alabama -- Department of Neurology/Epilepsy Center
mi
from
Birmingham, AL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Alabama -- Department of Neurology/Epilepsy Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
North Alabama Neuroscience Research Associates
mi
from
Huntsville, AL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
North Alabama Neuroscience Research Associates
mi
from
Huntsville, AL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Neurology Clinic PC
mi
from
Northport, AL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Neurology Clinic PC
mi
from
Northport, AL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Barrow Neurological Institute
mi
from
Phoenix, AZ
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Clinical Trials, Inc.
mi
from
Little Rock, AR
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Clinical Trials, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
UCSD - Thornton Hospital
mi
from
La Jolla, CA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
UCSD - Thornton Hospital
mi
from
La Jolla, CA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Southern California- Keck School of Medicine
mi
from
Los Angeles, CA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Southern California- Keck School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
West Los Angeles VA Healthcare Center
mi
from
Los Angeles, CA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
West Los Angeles VA Healthcare Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Delta Waves, INC
mi
from
Colorado Springs, CO
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Delta Waves, INC
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Colorado Department Of Neurology
mi
from
Denver, CO
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Colorado Department Of Neurology
mi
from
Denver, CO
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Florida-Shands/Jacksonville
mi
from
Jacksonville, FL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Florida-Shands/Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Miami
mi
from
Miami, FL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Lovelace Scientific Resources
mi
from
Sarasota, FL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Lovelace Scientific Resources
mi
from
Sarasota, FL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
McFarland Clinic, PC
mi
from
Ames, IA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
McFarland Clinic, PC
mi
from
Ames, IA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Kentucky
mi
from
Lexington, KY
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Mid-Atlantic Epilepsy and Sleep Center
mi
from
Bethesda, MD
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Mid-Atlantic Epilepsy and Sleep Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Henry Ford Hospital
mi
from
Detroit, MI
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
The Comprehensive Epilepsy Care Center For Children and Adults
mi
from
Chesterfield, MO
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
The Comprehensive Epilepsy Care Center For Children and Adults
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Beth Israel Med Ctr
mi
from
New York, NY
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Asheville Neurology Specialists, PA
mi
from
Asheville, NC
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Asheville Neurology Specialists, PA
mi
from
Asheville, NC
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Medical University of Ohio at Toledo
mi
from
Toledo, OH
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Medical University of Ohio at Toledo
mi
from
Toledo, OH
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Oregon Neurology PC
mi
from
Tualatin, OR
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Oregon Neurology PC
mi
from
Tualatin, OR
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Medical City Dallas Hospital
mi
from
Dallas, TX
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Medical City Dallas Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Neurological Clinic - Texas
mi
from
Dallas, TX
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Neurological Clinic - Texas
mi
from
Dallas, TX
Click here to add this to my saved trials